Soleno Therapeutics IncNASDAQ:SLNO
- LAST PRICE55.3100
- TODAY'S CHANGE (%)-1.9100 (-3.3380%)
- Bid / Lots55.3100/ 3
- Ask / Lots56.3000/ 8
- Open / Previous Close53.6200 / 57.2200
- Day Range
- 52 Week Range
- Volume141,359
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SLNO |
|---|---|---|
| 09:32 ET | 17785 | 55.075 |
| 09:33 ET | 26648 | 56.195 |
| 09:35 ET | 20512 | 55.585 |
| 09:37 ET | 19135 | 55.31 |
Today
Nov 14, 2024
Nov 11, 2024
DJ Soleno Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co., from 6:28AM ET on Monday Nov 11, 2024 by Dow Jones
6:28AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 6, 2024
*DJ Soleno Therapeutics 3Q Loss/Shr $1.83 >SLNO, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow JonesSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results, from 4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Soleno Therapeutics Inc | 2.5B | -16.7x | --- |
Geron Corp | 2.5B | -12.7x | --- |
Belite Bio Inc | 2.5B | -64.1x | --- |
Apogee Therapeutics Inc | 2.5B | -16.4x | --- |
Iovance Biotherapeutics Inc | 2.6B | -6.2x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -26.7x | --- |
Company Information
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.
Contact Information
- Headquarters
- 100 Marine Parkway, Suite 400REDWOOD CITY, CA, United States 94065
- Phone
- 650-213-8444
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Chief Operating Officer, Director
- Anish Bhatnagar
- Chief Financial Officer
- James Mackaness
- Senior Vice President - Clinical Development
- Michael Huang
- Senior Vice President - Clinical Operations
- Kristen Yen
- Vice President - Regulatory Affairs
- Patricia Hirano
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 43.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.45 |
EPS | $-3.31 |
Book Value | $4.97 |
P/E Ratio | -16.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
